SCIENTIFIC REPORTS
nature research

OPEN

Author Correction: Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesions

Published online: 24 March 2020

Marie-Laëtitia Thézénas, Bianca De Leo, Alexis Laux-Biehlmann, Cemsel Bafligil, Bernd Elger, Thomas Tapmeier, Karl Morten, Nilufer Rahmioglu, Stephanie G. Dakin, Philip Charles, Fernando Estrada Martinez, Graham Steers, Oliver M. Fischer, Joerg Mueller, Holger Hess-Stumpp, Andreas Steinmeyer, Sanjiv Manek, Krina T. Zondervan, Stephen Kennedy, Christian M. Becker, Catherine Shang, Thomas M. Zollner, Benedikt M. Kessler & Udo Oppermann

Correction to: *Scientific Reports* https://doi.org/10.1038/s41598-020-58362-3, published online 30 January 2020

In Figure 5A, the chemical structure is incorrect. As a result, the Figure legend,

"AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.

(**A**) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. (**B**) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (**C**) Target engagement results (2 mg/kg). (**D**) Changes in H_2O_2 in plasma. (**E**) Plasma exposure of PXS-4681A at day 2. (**F**) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment."

should read:

"AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model.

(**A**) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthesized according to literature procedures[37] (**B**) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (**C**) Target engagement results (2 mg/kg). (**D**) Changes in H_2O_2 in plasma. (**E**) Plasma exposure of PXS-4681A at day 2. (**F**) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment."

The correct Figure 5 and its accompanying legend appear below as Figure 1.



Time point - 2h - Day 2	[nM]
Bound concentration	91.5608501
Unbound concentration	77.918

Figure 1. AOC3 inhibitor PXS-4681A shows analgesic effects in the endometriosis inoculation mouse model. (**A**) Structure of AOC3 inhibitor PXS-4681A, orally administered BID at 2 mg/kg. The compound was synthesized according to literature procedures[37] (**B**) Unbound plasma levels of PXS-4681A (at 1-2-4 mg/kg). (**C**) Target engagement results (2 mg/kg). (**D**) Changes in H2O2 in plasma. (**E**) Plasma exposure of PXS-4681A at day 2. (**F**) Front/rear paw ratio measure using the dynamic weight bearing system indicating reduction of pain behaviour under treatment.